RCS - Oxford Biomedica PLC - OXB honoured at 2025 CDMO Leadership Awards Europe

Oxford BioMedicaAnnouncement

Yesterday 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251029:nRSc3698Fa&default-theme=true

RNS Number : 3698F  Oxford Biomedica PLC  29 October 2025

 

 

OXB honoured at 2025 CDMO Leadership Awards Europe in 'Cell & Gene
Therapy' category

 

Oxford, UK - 29 October 2025: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces it has been
recognised as a Champion in the 'Cell & Gene Therapy' category at the 2025
CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is
awarded to the highest-scoring CDMO in each category, based on direct feedback
from biopharmaceutical professionals who have recently partnered with CDMOs.

 

This recognition demonstrates OXB's excellence in quality, innovation and
service across its global network. It comes at a time of strong commercial
momentum for OXB, driven by increased demand for its end-to-end CDMO services
across key vector types and a growing portfolio of clients spanning all stages
of development.

 

Dr. Sebastien Ribault, Chief Business Officer of OXB, said: "We are honoured
to receive this recognition from the CDMO Leadership Awards Europe. It
reflects the trust and satisfaction of our clients and the dedication of our
teams across the UK, US and France. As demand continues to grow, we remain
committed to supporting our clients in delivering the next generation of
transformative therapies to patients around the world."

 

 

-Ends-

 

Enquiries:

OXB:

T: +44 (0) 1865 783 000 / E: partnering@oxb.com (mailto:partnering@oxb.com)

Sebastien Ribault, Chief Business Officer

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

About the CDMO Leadership Awards

The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science
Connect. Winners are selected based on primary research conducted by
Orientation Marketing, reflecting direct feedback from biopharmaceutical
professionals who have recently partnered with CDMOs. The awards recognize
contract development and manufacturing organizations that deliver excellence
in quality, capabilities, expertise, reliability, compatibility, and service.
Learn more at www.cmoleadershipawards.com
(https://www.cmoleadershipawards.com/) .

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMLBJTMTATBAA



            Copyright 2019 Regulatory News Service, all rights reserved